Clinical trial
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer…
NCT00005942 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005942 |
|---|---|
| Title | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy |
| Official title | Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation |
| Intervention type | Drug, Other |
| Interventions | liposomal daunorubicin citrate, semaxanib, laboratory biomarker analysis |
| Enrollment | 37 |
| Start date | Mar 1, 2000 |
| Primary completion | Dec 1, 2000 |
| First posted | May 26, 2004 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: